Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma (IMAGE)
Caption
Figure 3: Survival curves of patients with and without immune related adverse events.
Credit
Copyright: © 2025 da Fonseca et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content